Skip to main content
. Author manuscript; available in PMC: 2018 Feb 8.
Published in final edited form as: J Psychopharmacol. 2017 Dec 14;32(1):3–29. doi: 10.1177/0269881117741766

Consensus recommendations of pharmacological treatment of co-occurring conditions and symptoms in children and adults with ASD.

Children Adults
Mood disorders Decision on treatment needs to be made on a case by case basis. Follow the British Association for Psychopharmacology (BAP) guidelines for treating depression
(strength of recommendation: S)
Decision on treatment needs to be made on a case by case basis. Follow the British Association for Psychopharmacology (BAP) guidelines for treating depression
(strength of recommendation: S)
Anxiety disorders Consider a cautious trial of an SSRIs followed by risperidone if poor response. Monitor for worsening of anxiety in some children.
(strength of recommendation: B)
Decision on treatment needs to be made on a case by case basis. Follow the British Association for Psychopharmacology (BAP) guidelines for treating anxiety
(strength of recommendation: S)
Sleep disorders Melatonin, if possible, in combination with a behavioural intervention.
(strength of recommendation: A)

Prolonged use of benzodiazepines and related GABA agonists is not recommended.
(strength of recommendation: S)
Melatonin, if possible, in combination with behavioural intervention (extrapolation from findings in children)
(strength of recommendation: S)
Prolonged use of benzodiazepines and related GABA agonists is not recommended
(strength of recommendation: S)
Irritability Risperidone or aripiprazole but only when behavioural or educational approaches have failed.

(strength of recommendation: A)
Decision on treatment needs to be made on a case by case basis.
Aripiprazole or risperidone or an SSRI should only be considered cautiously and after considering alternatives
(strength of recommendation: S)
ADHD First line: methylphenidate
Second line: atomoxetine, or α2A receptor agonist.
Children with ASD may experience more side-effects and show less response than non-ASD patients with ADHD
(strength of recommendation: A)
Decision on treatment needs to be made on a case by case basis.
Follow the British Association for Psychopharmacology (BAP) guidelines for treating ADHD

(strength of recommendation: S)
Tic disorders and Tourette’s syndrome Decision on treatment needs to be made on a case by case basis

(strength of recommendation: S)
Decision on treatment needs to be made on a case by case basis

(strength of recommendation: S)